

impedimed

ASX ANNOUNCEMENT

SOZO™ Launched – First Product for Health and Wellness Markets

Brisbane, Australia and Carlsbad, Calif., 11 August, 2016 - ImpediMed Limited (ASX: IPD) announced today that SOZO™, the first product on its new population health platform that allows consumers and patients to measure and track their body composition, fluid status and hydration in a variety of settings, is available for global pre-order at www.hellosozo.com.

SOZO is an intuitive digital health device and wellness platform that combines bioimpedance spectroscopy (BIS) technology with artificial intelligence to create a rapid, non-invasive scan of a person's body providing a precise and repeatable snapshot of a person's body composition, fluid status and hydration.

Predictive analytics in SOZO will access cloud-based historical health data to create customised plans for user's personal health and wellness goals, helping individuals better manage their health conditions and track their wellness goals.

Compatible with iOS and Android devices, SOZO weighs just under one kilogram and includes eight body sensors and four weight sensors to measure body composition, fluid status and hydration. SOZO applications running on a user's mobile device or tablet will provide a variety of features for individuals and providers to monitor personal performance.

"We are fulfilling our vision of population health in the ecosystem of health and wellness. The SOZO platform and our growing pipeline of new and innovative products will position us at the forefront of the digital health revolution. Innovation is at our core and will become the life blood of the organisation. The future is now." said Richard Carreon, Managing Director and CEO of ImpediMed.

The suite of SOZOfit products that are being launched will be sold direct to consumers via the company's digital marketing channels. We expect to begin shipping our first customer orders by late December 2016.

The suite of SOZOmed products for specific health conditions are being finalised, and we expect to receive regulatory clearance for these indications as we move forward.

Additional product details and videos are available at www.hellosozo.com and at https://www.youtube.com/watch?v=0uMBA2II_qA&feature=youtu.be.

Richard Carreon
Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contacts:

For personal use only

In Australia:

Kyahn Williamson, Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

In the US:

Paul Maccabee/Andy Pollen, Maccabee PR

T: +1 612-337-0087

E: paul@maccabee.com; andy@maccabee.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.

For personal use only